China’s National Medical Products Administration approved Carsgen Therapeutics’ satricabtagene autoleucel (satri-cel, CT-041), marking the first global approval of a CAR T therapy for solid tumors. The autologous Claudin18.2-targeted therapy is indicated for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines. The decision follows trial evidence presented by Carsgen showing a progression-free survival benefit versus physician’s choice chemotherapy arms and an acceptable safety profile. The regulatory clearance provides a template for how solid-tumor CAR Ts may be positioned as immuno-oncology options beyond hematologic indications. For the field, the approval is likely to accelerate competitive activity around antigen selection, manufacturing processes, and conditioning regimens that improve trafficking and persistence in solid tumor settings. Watch items include post-approval real-world performance and whether additional indications follow as antigen-driven strategies expand.